darovasertib
Sponsor Ideaya Biosciences, INC. · listed as IDYA
darovasertib is a drug asset sponsored by Ideaya Biosciences, INC., listed as IDYA. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jan 15, 2027 (day precision, medium confidence), tied to trial NCT05987332. That trial is in Phase 2/3 and currently active not recruiting, studying Metastatic Uveal Melanoma. It appears across 3 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for darovasertib in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT05987332 catalyst | Phase 2/3 | Active, not recruiting | 2027-01-15 | Experimental | IDEAYA Biosciences | Metastatic Uveal Melanoma |
| NCT07015190 | Phase 3 | Recruiting | 2030-10 | Experimental | IDEAYA Biosciences | Uveal Melanoma |
| NCT07804186 | Phase 3 | Recruiting | 2034-03 | Experimental | IDEAYA Biosciences | Uveal Melanoma |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More IDYA catalysts